Introduction
Patients with inflammatory bowel diseases (IBD) have an increased risk of clostridium difficile infection (CDI). Cathelicidins are anti-microbial peptides that attenuate colitis and inhibit the effect of clostridial toxins. Plasma 25(OH)D stimulates production of cathelicidins.
Aim
To examine the association between plasma 25(OH)D and CDI in patients with IBD
Methods
From a multi-institutional IBD cohort, we identified patients with at least one measured plasma 25(OH)D. Our primary outcome was development of CDI. Multivariate logistic regression models adjusting for potential confounders were used to identify independent effect of plasma 25(OH)D on risk of CDI.
Results
We studied 3,188 IBD patients whom 35 patients developed CDI. Patients with CDI-IBD were older and had greater co-morbidity. The mean plasma 25(OH)D level was significantly lower in patients who developed CDI (20.4ng/ml) compared to non-CDI IBD patients (27.1ng/mL) (p=0.002). On multivariate analysis, each 1ng/ml increase in plasma 25(OH)D was associated with a 4% reduction in risk of CDI (OR 0.96, 95% CI 0.93 – 0.99, p = 0.046). Compared t o individuals with vitamin D > 20ng/mL, patients with levels < 20ng/mL were more likely to develop CDI (OR 2.27, 95% CI 1.16 – 4.44). The mean plasma 25(OH)D in patients with CDI who subsequently died was significantly lower (12.8+8.1ng/ml) compared to those who were alive at the end of follow-up (24.3+13.2ng/ml) (p=0.01).
Conclusion
Higher plasma 25(OH)D is associated with reduced risk of C difficile infection in patients with IBD. Further studies of therapeutic supplementation of vitamin D in IBD-CDI patients may be warranted.